Cosciens slides on trial failure of growth hormone deficiency diagnostic drug

COSCIENS Biopharma

27/08/2024 13:41

** U.S.-listed shares of Canadian drug developer Cosciens
Biopharma  CSCI.TO   CSCI.O  fall 39.9% to $3.52 premarket
    ** Co says its drug macimorelin, when used to diagnose
childhood-onset growth hormone deficiency, failed to meet the
main goal in a late-stage trial
    ** Says the drug showed a high false-positive diagnosis when
compared to current standard growth hormone stimulation tests
    ** Childhood-onset growth hormone deficiency occurs when the
pituitary gland doesn't produce enough growth hormone to
stimulate the body's growth
    ** Co says the data will be further analyzed and discussed
with health authorities 
    ** Up to last close, stock down 21.2% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))